Autoimmune RORγt Program May Portend Change Of Direction For Vitae
The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.
You may also be interested in...
Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.
Vitae's first-in-class ROR gamma t inhibitor shows significant reduction of PASI scores with two doses tested in Phase IIa, and a solid safety profile, despite some liver enzyme increases with the higher dose.
Now that its Alzheimer's partnership has ended and a diabetes tie-up is on uncertain ground, the computational drug-design firm has turned primarily to advancing psoriasis candidate VTP-43742.